New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries : vimarsana.com

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

03.11.2022 - SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) - Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a study1 that highlights the development and ...

Related Keywords

Mychoice Cdx , Thomas Slavin , Matt Scalo , Megan Manzari , Bracanalysis Cdx , Genetics Inc , Exchange Commission , Fast Company , World Most Innovative Companies , Myrisk Hereditary Cancer Test , Chief Medical Officer , Most Innovative Companies , Myriad Myrisk , Myrisk Hereditary Cancer , Health Illuminated , Myriad Genetics , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports ,